Characterization of tumor prognosis and sensitive chemotherapy drugs based on cuproptosis-related gene signature in ovarian cancer
Open Access
- 24 January 2025
- journal article
- research article
- Published by Springer Nature in BMC Women's Health
- Vol. 25 (1) , 1-15
Abstract
Cuproptosis is a novel form of cell death, acting on the tricarboxylic acid cycle in mitochondrial respiration and mediated by protein lipoylation. Other cancer cell death processes, such as necroptosis, pyroptosis, and ferroptosis, have been shown to play crucial roles in the therapy and prognosis of ovarian cancer. However, the role of cuproptosis in ovarian cancer remains unclear. The expression profiles of 10 cuproptosis-related genes were extracted from GSE140082. Kaplan-Meier survival and Cox proportional hazards regression were used to identify prognostic genes for constructing risk models. Following this, Least Absolute Shrinkage and Selection Operator regression was employed to construct a risk score model. Next, a nomogram was constructed to predict overall survival in ovarian cancer. Ultimately, our analysis compared the two groups across various dimensions, including clinical characteristics, tumor progression, metabolism-related pathways, immune landscape, and drug sensitivity. MTF1 and LIAS were identified as protective factors in ovarian cancer, with patients in the higher risk group being significantly associated with poorer survival. Furthermore, integrating the risk score with clinical characteristics in the nomogram demonstrated high specificity and sensitivity in predicting survival. A higher propotion of M2 macrophages, follicular helper T cells, and resting mast cells was observed in the high-risk group. Additionally, the IC50 values of Dasatinib, Bortezomib, Parthenolide, and Imatinib were significantly lower in the high-risk group. The study highlights the prognostic significance of cuproptosis-related genes and provides new insights into developing pharmacological therapeutic strategies targeting cuproptosis for the prevention and treatment of ovarian cancer.Keywords
Funding Information
- Undergraduate education quality construction comprehensive reform project (2022ZG282, 2022ZG282)
- cross-innovation talent project in Renmin Hospital of Wuhan University (JCRCZN-2022-016, JCRCZN-2022-016)
- National Natural Science Foundation of China (82071655)
- Natural Science Foundation of Hubei Province (2022CFB252)
This publication has 57 references indexed in Scilit:
- Elesclomol Loaded Copper Oxide Nanoplatform Triggers Cuproptosis to Enhance Antitumor ImmunotherapyAdvanced Science, 2024
- Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD‐L1 for Enhanced Cancer ImmunotherapyAdvanced Materials, 2023
- Investigations of cellular copper metabolism in ovarian cancer cells using a ratiometric fluorescent copper dyeJBIC Journal of Biological Inorganic Chemistry, 2022
- AKT-driven epithelial-mesenchymal transition is affected by copper bioavailability in HER2 negative breast cancer cells via a LOXL2-independent mechanismCellular Oncology, 2022
- Gene signature of m6A-related targets to predict prognosis and immunotherapy response in ovarian cancerJournal of Cancer Research and Clinical Oncology, 2022
- AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathwayCancer Letters, 2022
- The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancerBiomedicine & Pharmacotherapy, 2020
- Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human CancersCell Reports, 2018
- Changes in the Serum Levels of Trace Elements Before and After the Operation in Thyroid Cancer PatientsBiological Trace Element Research, 2016
- Combined effects of serum trace metals and polymorphisms of CYP1A1 or GSTM1 on non-small cell lung cancer: A hospital based case–control study in ChinaCancer Epidemiology, 2011